Dr Ola Landgren at ASH 2014: Final results from NCI phase II pilot study of carfilzomib, lenalidomide and dexamethasone in high-risk smouldering myeloma
At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Ola Landgren discusses the final results from the NCI phase II pilot study of carfilzomib, lenalidomide and dexamethasone in 12 pati...
Author: EMJ
Added: 01/13/2015
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts